A Study to Test the Efficacy and Safety of Bimekizumab in Study Participants

With Moderate to Severe Hidradenitis Suppurativa

(BE HEARD II)

​

ID #NCT04242498

​

Recruitment Status: recruiting as of August 2020

 

Estimated Completion Date: May of 2023

​

Sponsors and Collaborators: UCB Biopharma SRL

​

Information provided by (Responsible Party): UCB Biopharma SRL

​

Brief Summary: The purpose of the study is to test the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS).

​

Please link for complete details https://clinicaltrials.gov/ct2/show/NCT04242498

​

Locations: multiple locations please refer to link above for further information.

​

Contact: UCB Cares 1844599 ext 2273 UCBCares@ucb.com